Fasting hyperglycemic patients with hypertension
Conditions
Interventions
telmisartan 40-80 mg/day for 24 weeks
irbesartan 100-200 mg/day for 24 weeks
Sponsors
Department of Internal Medicine and Cardiology, Osaka City University Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) The patients with more than systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg with untreatment or treatment with antihypertensive medications except the inhibitors of renin-angiotensin system (ARB, ACEI, an renin inhibitor, an aldosterone receptor blocker). 2) The fasting blood glucose level is 110 mg/dL and more, and less than 126 mg/dL
Exclusion criteria
Exclusion criteria: 1) The patients with secondary hypertension 2) The patients with diagnosed diabetes which are treated with medication 3) The patients received a dialysis treatment 4) The patients with a history of hypersensitivity for test drugs 5) The women who are or may be pregnant 6) The patients with extremely poor bile secretion (total bilirubin more than 2.0 mg/dL) or severe hepatopathy (AST or ALT more than 100I U/L) 7) The patients judged inappropriate by the physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The variation of fasting blood glucose level 24 weeks after medical treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) The variation of blood pressure 24 weeks after medical treatment 2) The variation of fasting insulin, HOMA-IR, HbA1c, adiponectin and high sensitive CRP levels 24 weeks after medical treatment 3) The variation of total cholesterol, low density lipoprotein, high density lipoprotein and triglyceride levels 24 weeks after medical treatment 4) The rate of onset of new diabetes 24 weeks after medical treatment 5) The achievement rate of targeted blood pressure 24 weeks after medical treatment | — |
Countries
Japan
Contacts
Public ContactYasukatsu Izumi
Osaka City University Medical School Department of Pharmacology
Outcome results
None listed